GEF-Inhibitors: New small molecules for the treatment of autoimmune and malignant diseases
Scientists at the University of Bonn have identified new small molecules which can be used for the treatment of diseases characterized by alterations of proteins which are affected by Guanine nucleotide Exchange Factors (GEFs). Proteins targeted by GEFs are involved in integrin signalling, vesicle transport, or MAPK-signalling. These processes play an important role in the modulation of the immune response. Therefore, abnormal activation of the target proteins of GEFs can cause autoimmune and tumor diseases in humans.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Detector for continuously monitoring toxic gases
The material could be made as a thin coating to analyze air quality in industrial or home settings over time. Most systems used to detect toxic gases in industrial or…
On the way for an active agent against hepatitis E
In order to infect an organ, viruses need the help of the host cells. “An effective approach is therefore to identify targets in the host that can be manipulated by…
A second chance for new antibiotic agent
Significant attempts 20 years ago… The study focused on the protein peptide deformylase (PDF). Involved in protein maturation processes in cells, PDF is essential for the survival of bacteria. However,…
